Abstract
The purpose of the study is to evaluate the tumour enhancing characteristics and biodistribution of a newly developed metalloporphyrin derivative, HOP-9P (13, 17-bis (1-carboxypropionyl) carbamoylethyl-3, 8-bis (1-phenylpropyloxyethyl)-2,7,12,18-tetra- methyl-porphynato manganese (III)). Seven mice bearing SCC VII tumours were imaged using T1-weighted conventional spin echo magnetic resonance images before and 5 min, 2 h and 24 h after intravenous injection of 0.1 mmol/kg of HOP-9P. For the acquired images, signal intensities of the tumour, muscle and oil-phantom were measured. Then, tumor/oil and tumor/muscle signal intensity ratios were calculated. Nineteen mice were sacrificed before or after the administration of HOP-9P (at 5 min, 2 h and 24 h), and the biodistribution of manganese in the tumour, muscle, liver, blood and kidneys was measured using optical emission spectrometers and was expressed as micrograms of manganese per gram of tissue. The tumour/muscle signal intensity ratio at 24 h (3.18 ± 0.34) was significantly higher than precontrast ratio (1.77 ± 0.20) (P < 0.05). The biodistribution assessment of manganese demonstrated that HOP-9P gradually and consistently accumulated in the tumour to reach the highest concentration at 24 h (3.49 ± 1.22 μ gMn/g). It is concluded that HOP-9P is a potential tumour-specific MR contrast agent. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Calzavara-Pinton PG, Szeimies RM, Ortel B and Zane C (1996) Photodynamic therapy with systemic administration of photosensitizers in dermatology. [Review] [35 refs]. J Photochem Photobiol B 36: 225–231
Chen CW, Cohen JS, Myers CE and Sohn M (1984) Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 168: 70–74
Dagan A, Gatt S, Cerbu-Karabat S, Maziere JC, Maziere C, Santus R, Engelhardt EL, Yeh KA, Stobbe CC and Fenning MC (1995) Uptake by cells and photosensitizing effectiveness of novel pheophorbide derivatives in vitro. Int J Cancer 63: 831–839
Fiel RJ, Mark E, Button T, Gilani S and Musser D (1988) Mechanism of the localization of manganese (III) mesotetra(4-sulfonatophenyl) porphine in mice bearing L1210 tumors. Cancer Lett 40: 23–32
Hill RA, Garrett J, Reddi S, Esterowitz T, Liaw LH, Ryan J, Shirk J, Kenney M, Shimuzu S and Berns MW (1996) Photodynamic therapy (PDT) of the ciliary body with silicon naphthalocyanine (SINc) in rabbits. Lasers Surg Med 18: 86–91
Jain RK (1987) Transport of molecules in the tumor interstitium: a review. [Review] [122 refs]. Cancer Res 47: 3039–3051
Kessel D and Chou TH (1983) Tumor-localizing components of the porphyrin preparation hematoporphyrin derivative. Cancer Res 43: 1994–1999
Kessel D (1992) Photodynamic therapy and neoplastic disease. [Review] [78 refs]. Oncol Res 4: 219–225
Kobayashi M, Tajiri H, Hayashi T, Kuroki M and Sakata I (1999) Tumor-enhancement effect of a Mn3+ metalloporphyrin derivative (ATN-4T) in magnetic resonance imaging. Cancer Lett 137: 83–89
Koenig SH, Brown RD and Spiller M (1987) The anomalous relaxivity of Mn3+ (TPPS4). Magn Reson Med 4: 252–260
Kostenich G, Orenstein A, Roitman L, Malik Z and Ehrenberg B (1997) In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. J Photochem Photobiol, B39: 36–42
Lapes M, Petera J and Jirsa M (1996) Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulphophenyl)-porphin (TPPS4). J Photochem Photobiol B 36: 205–207
Matsumura A, Shibata Y, Yamamoto T, Yoshida F, Isobe T, Nakai K, Hayakawa Y, Kiriya M, Shimojo N, Ono K, Sakata I, Nakajima S, Okumura M and Nose T (1999) A new boronated porphyrin (STA-BX909) for neutron capture therapy: an in vitro survival assay and in vivo tissue uptake study. Cancer Lett 141: 203–209
McIlroy BW, Curnow A, Buonaccorsi G, Scott MA, Bown SG and MacRobert AJ (1998) Spatial measurement of oxygen levels during photodynamic therapy using time-resolved optical spectroscopy. J Photochem Photobiol B 43: 47–55
Megnin F, Faustino PJ, Lyon RC, Lelkes PI and Cohen JS (1987) Studies on the mechanism of selective retention of porphyrins and metalloporphyrins by cancer cells. Biochim Biophys Acta 929: 173–181
Miura M, Micca PL, Fisher CD, Heinrichs JC, Donaldson JA, Finkel GC and Slatkin DN (1996) Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: biodistribution and toxicity in tumor-bearing mice. Int J Cancer 68: 114–119
Nakajima S, Takemura T and Sakata I (1995) Tumor-localizing activity of porphyrin and its affinity to LDL, transferrin. Cancer Lett 92: 113–118
Nakajima S, Sakata I, Hirano T and Takemura T (1998) Therapeutic effect of interstitial photodynamic therapy using ATX-S10(Na) and a diode laser on radio-resistant SCCVII tumors of C3H/He mice. Anticancer Drugs 9: 539–543
Nakajima S, Moriyama T, Hayashi H, Sakata I, Nakae Y and Takemura T (2000) Hemopexin as a carrier protein of tumor-localizing Ga-metalloporphyrin- ATN-2. Cancer Lett 149: 221–226
Niendorf A, Nagele H, Gerding D, Meyer-Pannwitt U and Gebhardt A (1995) Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 61: 461–464
Oenbrink G, Jurgenlimke P and Gabel D (1988) Accumulation of porphyrins in cells: influence of hydrophobicity aggregation and protein binding. Photochem Photobiol 48: 451–456
Reyftmann JP, Morliere P, Goldstein S, Satus R, Dubertret L and Lagrange D (1984) Interaction of human serum low density lipoproteins with porphyrins: a spectroscopic and photochemical study. Photochem Photobiol 40: 721–729
Rowinsky EK (1999) Novel radiation sensitizers targeting tissue hypoxia. [Review] [84 refs]. Oncology (Huntingt) 13: 61–70
Shibata Y, Matsumura A, Yamamoto T, Nakagawa K, Yoshii Y, Nose T, Sakata I, Nakajima S, Hayakawa Y and Ono K (1998) Neutron capture therapy with a new boron-porphyrin compound in the rat 9L glioma model. J Exp Clin Cancer Res 17: 285–289
Shopova M, Wohrle D, Stoichkova N, Milev A, Mantareva V, Muller S, Kassabov K and Georgiev K (1994) Hydrophobic Zn(II)-naphthalocyanines as photodynamic therapy agents for Lewis lung carcinoma. J Photochem Photobiol B 23: 35–42
Suzuki T, Nakano K, Tomiyoshi K, Sakata I, Endo K and Yamanaka H (1996) Contrast enhancement of PC-3 prostate cancer for magnetic resonance imaging: animal studies using tumor-localizing Mn-metalloporphyrin (THF-Mn-Asp). J Urol 156: 1850–1852
Takemura T, Ohta N, Nakajima S and Sakata I (1992) The mechanism of photosensitization in photodynamic therapy: chemiluminescence caused by photosensitization of porphyrins in saline containing human serum albumin. Photochem Photobiol 55: 137–140
Takemura T, Nakajima S and Sakata I (1994) Tumor-localizing fluorescent diagnostic agents without phototoxicity. Photochem Photobiol 59: 366–370
Viala J, Vanel D, Meingan P, Lartigau E, Carde P and Renschler M (1999) Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 212: 755–759
Woodburn KW, Fan Q, Kessel D, Luo Y and Young SW (1998) Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. J Invest Dermatol 110: 746–751
Zhu L, Hope TJ, Hall J, Davies A, Stern M, Muller-Eberhard U, Stern R and Parslow TG (1994) Molecular cloning of a mammalian hyaluronidase reveals identity with hemopexin, a serum heme-binding protein. J Biol Chem 269: 32092–32097
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Takehara, Y., Sakahara, H., Masunaga, H. et al. Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice. Br J Cancer 84, 1681–1685 (2001). https://doi.org/10.1054/bjoc.2001.1802
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1802